Glytec

Glytec is a commercial-stage digital health leader focused on transforming inpatient and system-wide diabetes management. Its core FDA-cleared technology, Glucommander, provides algorithm-based insulin dosing guidance, which is now integrated into the broader GlytecOne platform offering care enablement, decision support, performance analytics, and population health intelligence. The company serves over 400 hospital clients, leverages over 50 billion data points, and is strategically positioned to help health systems comply with new CMS eCQM reporting mandates for glycemic events starting in 2026. Glytec demonstrates strong value with reported ROI of 6-8x, significant cost savings per severe hypoglycemic event, and substantial improvements in clinical outcomes like reduced hypoglycemia and readmissions.

GlytecOne Intelligent Glycemic Management Platform, a unified SaaS platform integrating FDA-cleared Glucommander insulin dosing algorithms, clinical decision support (Command Center), workflow automation, performance analytics, and population health intelligence for hospitals.

Glytec competes in the clinical decision support software market for inpatient diabetes management. Key competitors include embedded tools within major EHRs (Epic, Cerner), other standalone glycemic management software companies, and manual protocol consultants. Glytec differentiates with its FDA-cleared dosing algorithms, unified four-pillar platform, extensive outcome data, and focus on CMS eCQM readiness.